/PRNewswire/ On World Heart Day, the World Heart Federation (WHF) is calling for urgent action on climate change and health inequity, saying millions more.
TricValve® Transcatheter Bicaval Valves System Receives CE Mark
HONG KONG, May 20, 2021 /PRNewswire/ – OrbusNeich
® Medical Company Ltd. and P&F Products & Features®, under the joint partnership OrbusNeich P&F, today announced that the TricValve® Transcatheter Bicaval Valves System has received CE mark approval.
The TricValve® Transcatheter Bicaval Valve (bioprosthesis) is developed for the treatment of caval reflux present in cases of severe tricuspid regurgitation, without removal of the defective tricuspid valve. The bioprosthesis is available in different diameters for each model (SVC and IVC) and specifically designed to adapt to the anatomic features of the superior and inferior vena cava. TricValve is a safe and simple valve system for patients with severe tricuspid regurgitation, said Dr Shaiful Azmi Yahaya, Head of the Cardiology Department at the National Heart Institute, Kuala Lumpur, Malaysia. He added TricValve provides a new treatment option for patient
TricValve Transcatheter Bicaval Valves System Receives CE Mark
HONG KONG, May 20, 2021 /PRNewswire/ OrbusNeich Medical Company Ltd. and P&F Products & Features, under the joint partnership OrbusNeich P&F, today announced that the TricValve Transcatheter Bicaval Valves System has received CE mark approval.
The TricValve Transcatheter Bicaval Valve (bioprosthesis) is developed for the treatment of caval reflux present in cases of severe tricuspid regurgitation, without removal of the defective tricuspid valve. The bioprosthesis is available in different diameters for each model (SVC and IVC) and specifically designed to adapt to the anatomic features of the superior and inferior vena cava.
/PRNewswire/ OrbusNeich® Medical Company Ltd. and P&F Products & Features®, under the joint partnership OrbusNeich P&F, today announced that the TricValve®.